Biodesix Q2 2026 net loss narrows 37% to $7.3 million; revenue climbs 34% to $26.9 million

Reuters2026/08/05 20:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Biodesix posted Q2 2026 revenue of USD 26.9 million, up 34% year over year; GAAP net loss narrowed 37% to USD 7.3 million.
Gross margin improved 2 percentage points to 82%, as diagnostic testing volumes climbed 38% to 20,900 on expanded payer coverage.
Diagnostic Testing revenue rose 42% to USD 25.4 million, while Development Services revenue fell to USD 1.5 million from USD 2.1 million on project timing.
Non-GAAP adjusted EBITDA loss narrowed 56% to USD 3.2 million; cash and cash equivalents increased 17% to USD 30 million, including USD 6.5 million from the at-the-market program.
Biodesix maintained FY 2026 revenue guidance of USD 108 million to USD 114 million, targeting roughly 80% gross margin and continued adjusted EBITDA improvement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biodesix Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608051601PRIMZONEFULLFEED9801945) on August 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Biodesix Q2 2026 net loss narrows 37% to $7.3 million; revenue climbs 34% to $26.9 million

You may also like

Crypto prices